4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Total Liabilities data on file, last reported at $61.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 32.74% year-over-year to $61.1 million in Q1 2026; TTM through Mar 2026 was $61.1 million, a 32.74% increase from a year earlier, with the FY2025 full-year figure at $61.0 million, up 22.64% from the prior year.
• Total Liabilities for Q1 2026 stood at $61.1 million, roughly flat from $61.0 million in the prior quarter.
• Over the last five years, Total Liabilities for FDMT reached as high as $61.1 million in Q1 2026 and fell as low as $25.4 million in Q1 2023.
• Historically, Total Liabilities has averaged $39.6 million across 5 years, with a median of $31.8 million in 2024.
• Across the five-year window, Total Liabilities soared 112.9% in 2022 and declined 11.97% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $30.5 million in 2022, then grew by 5.09% to $32.1 million in 2023, then jumped by 55.26% to $49.8 million in 2024, then rose by 22.64% to $61.0 million in 2025, then advanced by 0.04% to $61.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $61.1 million in Q1 2026, $61.0 million in Q4 2025, and $55.0 million in Q3 2025.